Using tranexamic acid to reduce bleeding in major colorectal surgery

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of preoperative tranexamic acid (TXA) in reducing bleeding during and after major colorectal surgery. It is a prospective, pragmatic, randomized trial comparing patients receiving TXA to those who do not. The study will measure changes in hemoglobin levels and the incidence of bleeding complications within 30 days post-surgery, while also assessing any potential increase in thromboembolic events. Participants will receive TXA intravenously at the start and end of their surgical procedure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults 18 years or older
2. Undergoing elective or non-elective inpatient abdominal and pelvic colorectal surgery

Exclusion Criteria:

1. Creatinine clearance less than 30 mL/minute
2. Long-term dialysis
3. Known defective color vision (color blind)
4. Pregnancy
5. History of venous or arterial thromboembolism, or active thromboembolic disease
6. Disseminated intravascular coagulation (DIC) - clinically suspected and/or confirmed by platelet count on CBC, fibrinogen, INR and PTT.

Where it's running

• Cleveland Clinic Fairview Hospital
  Cleveland, Ohio, United States Recruiting

Study contacts

• Principal investigator: Kristen A Ban, MD MS — The Cleveland Clinic
• Study coordinator: Kristen A Ban, MD MS
• Email: bank4@ccf.org
• Phone: 2164766961

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing blood thinners for patients on ECMO support

  This study is testing whether two different blood thinners, argatroban and enoxaparin, can work as well as the usual treatment, heparin, for patients on ECMO support.

  Recruiting Phase 4 Medical University of Vienna · Vienna, State of Vienna · NCT06442267

• Antiplatelet-Only versus Antiplatelet plus Low-Dose Rivaroxaban after Heart Events

  In adults 65 or older with prior heart events and certain arterial diseases, this study tests whether continuing clopidogrel alone is no worse than adding low-dose rivaroxaban to aspirin-based therapy.

  Recruiting Phase 4 Seoul National University Bundang Hospital · Seongnam-si, Gyeonggi-do · NCT07796217

• Tailored lower‑intensity blood thinner plan after left atrial appendage closure to prevent stroke

  This project tests whether people with non‑valvular atrial fibrillation who get a left atrial appendage closure can stop blood thinners after taking low‑dose apixaban (2.5 mg twice daily) for 3 months, compared with people who stay on standard‑dose DOACs.

  Recruiting National Medical Research Center for Therapy and Preventive Medicine · Moscow · NCT07575867

• Multi-omics search for clotting and bleeding markers in coronary heart disease

  This project will test whether combining proteins, metabolites, genes, sugar tags, and heart images can better predict clotting and major bleeding in people with coronary heart disease on dual antiplatelet therapy.

  Recruiting at 3 sites Chinese Academy of Medical Sciences, Fuwai Hospital · Zhengzhou, Henan and 2 other locations · NCT07523880

• Apixaban vs Warfarin in HeartMate 3 LVAD Patients

  This study tests whether apixaban can replace warfarin to prevent clots and bleeding problems in adults with an implanted HeartMate 3 LVAD for at least 3 months.

  Recruiting Phase 3 Columbia University · New York, New York · NCT07471139

• Safety of perioperative blood thinner management in people with cancer undergoing surgery or procedures

  This study tests how safe current practices are for stopping or continuing blood thinners in adults with cancer who are having surgery or procedures, to see if bleeding or clots are affected.

  Recruiting Ottawa Hospital Research Institute · Ottawa · NCT07372716

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.